JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miceli, R.
Right arrow Articles by Connolly, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miceli, R.
Right arrow Articles by Connolly, K.

Vol. 290, Issue 1, 464-471, July 1999

Efficacy of Keratinocyte Growth Factor-2 in Dextran Sulfate Sodium-Induced Murine Colitis

Renée Miceli, Melissa Hubert, Gemma Santiago, Da-Lin Yao, Timothy A. Coleman, Kathleen A. Huddleston and Kevin Connolly

Department of Pharmacology, Human Genome Sciences, Inc., Rockville, Maryland

The purpose of this study was to determine the efficacy of a novel human protein, keratinocyte growth factor-2 (KGF-2), in a model of murine colitis induced by ad libitum exposure to a 4% solution of dextran sulfate sodium (DSS) in the drinking water. Initial evaluation of KGF-2 was based on its ability to reduce weight loss, stool score, and histological score in mice exposed to DSS for 7 days. When KGF-2 (0.1-10.0 mg/kg i.p. or s.c.) was injected daily into DSS-treated mice from day 0 to 7, it significantly reduced all three parameters in a dose-response fashion, with a minimum effective dose of between 1 and 3 mg/kg. When KGF-2 was given therapeutically, starting 4 days after initiation of the 7-day DSS treatment, the 3- but not the 0.5-mg/kg dose significantly enhanced weight recovery after discontinuation of DSS treatment. When DSS treatment was prolonged beyond the normal 7 days, therapeutic intervention on day 2 or 4 also significantly reduced mortality, weight loss, and stool score at the 1- and 3-mg/kg dose. Therapeutic treatment also resulted in reduction of colon myloperoxidase levels by more than 50%. These experiments suggest that KGF-2 may be clinically useful in the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.

0022-3565/99/2901-0464$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. O. Freytes, V. Ratanatharathorn, C. Taylor, C. Abboud, N. Chesser, A. Restrepo, J. Arango, and D. Odenheimer
Phase I/II Randomized Trial Evaluating the Safety and Clinical Effects of Repifermin Administered to Reduce Mucositis in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
Clin. Cancer Res., December 15, 2004; 10(24): 8318 - 8324.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
F. R. Byrne, C. L. Farrell, R. Aranda, K. L. Rex, S. Scully, H. L. Brown, S. A. Flores, L. H. Gu, D. M. Danilenko, D. L. Lacey, et al.
rHuKGF ameliorates symptoms in DSS and CD4+CD45RBHi T cell transfer mouse models of inflammatory bowel disease
Am J Physiol Gastrointest Liver Physiol, April 1, 2002; 282(4): G690 - G701.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. T. Abreu, E. T. Arnold, J. Y. C. Chow, and K. E. Barrett
Phosphatidylinositol 3-Kinase-dependent Pathways Oppose Fas-induced Apoptosis and Limit Chloride Secretion in Human Intestinal Epithelial Cells. IMPLICATIONS FOR INFLAMMATORY DIARRHEAL STATES
J. Biol. Chem., December 7, 2001; 276(50): 47563 - 47574.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. S. Han, F. Li, L. Holt, K. Connolly, M. Hubert, R. Miceli, Z. Okoye, G. Santiago, K. Windle, E. Wong, et al.
Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats
Am J Physiol Gastrointest Liver Physiol, November 1, 2000; 279(5): G1011 - G1022.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.